Teleflex Features ARROW® JACC with Chlorag+ard® Technology, the Only Long-Term Antimicrobial and Ant

Teleflex Features ARROW^®JACC with Chlorag⁺ard^®Technology, the Only Long-Term Antimicrobial and Antithrombogenic CVC, and ARROW^®VPS G4™ Vascular Positioning Device at the 2013 AVA Conference

New Innovations from Teleflex Reinforce its ARROW^®Brand Commitment to "Never Settle" Towards the Goal of Zero Complications in Vascular Care

LIMERICK, Pa--(BUSINESS WIRE)-- Teleflex Incorporated (NYS: TFX) , a leading global provider of medical devices for critical care and surgery, will feature two new ARROW^® Vascular Access innovations at the annual Association for Vascular Access conference this week. The ARROW^® VPS G4™ Device is a next generation Vascular Positioning System^® offering state-of-the-art design and technology for precise and accurate CVC and PICC tip positioning. It features easy-to-follow symbols with further enhancements such as statement of final catheter position and Wi-Fi access to make central catheter placements easier at the bedside. As in previous models, it is indicated for use as an alternative method to fluoroscopy or chest X-ray for central venous catheter tip placement confirmation in adult patients, when a steady Blue Bullseye symbol is obtained.

The ARROW^® JACC (Jugular Axillo-subclavian Central Catheter) with Chlorag⁺ard^® Technology is a small-french size antimicrobial and antithrombogenic catheter that is indicated for both acute and long-term use. It is designed specifically to support the emergence of Central Venous Catheter placement by Vascular Access Specialists. Teleflex, through its ARROW^® brand, supports and applauds clinicians in expanding their scope of practice to include CVC insertion, now legal in more than forty states.

"Teleflex is proud to introduce these innovative new ARROW^® devices," states Kathy Conner, Vice President of Global Marketing. "Because the incidence of infection, occlusion and thrombosis for both CVCs and PICCs is so significant, we are excited to now provide Chlorag⁺ard^® Technology on ARROW^® JACC following our 2011 introduction of ARROW^® PICC with Chlorag⁺ard^® Technology. Chlorag⁺ard^® is another tool we offer enabling clinicians to fight for zero complications in vascular care. Similarly, our next generation ARROW^® VPS G4™ Device uses precise and easy-to-use technology to place CVCs and PICCs in the correct position. We are thrilled with the clinical results VPS^® Technology brings to the bedside. It has benefited thousands of patients by eliminating their need for a chest X-ray, allowing them to receive their needed therapy more quickly."

In addition to featuring nine posters unique to Teleflex employees or ARROW^® Vascular Access products, the company is sponsoring two symposia during the conference. One highlights placement of CVCs via the Vascular Access Specialist: "Breaking Through: A Guide to Placing CVCs," along with a Platinum Showcase focusing on insertion site alternatives: "When the Arm Is No Longer an Option." The second symposium highlights significant advancements in tip positioning technology with two presentations: "New Advances in ARROW^®Vascular Positioning Technology" and "Comparative Data Using PICC Placement Technology - 800 Clinical Cases."

Additional information may be found at arrowintl.com.

About Teleflex Incorporated

Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, Pa, Teleflex employs approximately 11,500 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company's website at teleflex.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, ARROW, Chlorag⁺ard, Vascular Positioning System, VPS and VPS G4 are registered trademarks of Teleflex Incorporated or its affiliates.
©2013 Teleflex Incorporated. All rights reserved. 2013-2427

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS:

The article Teleflex Features ARROW® JACC with Chlorag+ard® Technology, the Only Long-Term Antimicrobial and Antithrombogenic CVC, and ARROW® VPS G4™ Vascular Positioning Device at the 2013 AVA Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.